IJC
International Journal of Cancer

Anal squamous intraepithelial lesions are frequent among young HIV-infected men who have sex with men followed up at the Spanish AIDS Research Network Cohort (CoRIS-HPV)

Cristina González[1], Montserrat Torres[2], Amparo Benito[3], Jorge del Romero[4], Carmen Rodríguez[4], María Fontillón[5], Mónica Trastoy[5], Pompeyo Viciana[5], Julia del Amo[1], Marta Ortiz[2] and Beatriz Hernández-Novoa[3]; on behalf of the CoRIS-HPV Study Group

[1] Centro Nacional de EpidemiologÚa, Instituto de Salud Carlos III, 28029 Madrid, Spain
[2] Centro Nacional de MicrobiologÚa, Instituto de Salud Carlos III, 28220 Madrid, Spain
[3] Hospital Universitario Ramœn y Cajal-IRYCIS, 28034 Madrid, Spain
[4] Centro Sanitario Sandoval, 28010 Madrid, Spain
[5] Hospital Virgen del Rocio, 41013 Sevilla, Spain

The aim of our study was to determine the baseline prevalence of anal squamous intraepithelial lesions (SIL) and associated risk factors in HIV-infected men who have sex with men (MSM) in a Spanish ongoing multicenter cohort. CoRIS-HPV started in 2007, nested in the Spanish AIDS Research Network Cohort (CoRIS). Anal liquid cytology testing was performed. High-risk human papillomavirus (HR-HPV) infection was determined, and positive samples were genotyped. We analyzed all subjects up to April 2011. Multivariate logistic regression analyses were performed. A total of 551 subjects with baseline anal liquid cytologies were analyzed; 37.0% negative for intraepithelial lesion, 9.0% atypical squamous cells of uncertain significance (ASCUS), 41.0% low-grade SIL, 4.0% high-grade SIL and 9.0% inadequate. Prevalence of anal SIL (excluding ASCUS) in valid samples ($n = 450$) was 54.7% (95% confidence interval [CI] = 49.9–59.3). Globally HR-HPV prevalence was 81.7% (95% CI = 78.0–85.2). Multiple infections (≥2 HR-HPV genotypes) were documented in 77.7% (95% CI = 73.1–82.0). The only risk factor associated with anal SIL was the number of HR-HPV types; MSM with five or more HR-HPV genotypes had an odds ratio (OR) of anal SIL seven times greater (OR = 7.4; 95% CI = 2.8–19.6) than those with one HR-HPV genotype. No associations were found for age, educational level, smoking, geographical origin, CD4 T-cell count, antiretroviral treatment or number of sexual partners. The prevalence of anal SIL in young HIV-positive MSM is high, and the main risk factor is multiple infections with HR-HPV types.

Epidemiology

High-risk human papillomavirus (HR-HPV) is an etiologic agent of anal cancer.[1] Percentages of HPV coinfection are very high among HIV-infected patients, especially in men who have sex with men (MSM).[2–5]

In the past years, most studies carried out in HIV-infected MSM in the United States and Europe have documented HPV prevalence around 85.0–95.0%.[5–7] In Spain, few data are available on anal HPV prevalence; Sirera *et al.* reported a HR-HPV prevalence of 83.0% in 52 MSM. The same group in a recent study of anal condylomata in 640 HIV-infected men (473 MSM) reported an overall prevalence of anal HPV of 73%.[8] In 2011, Ortiz *et al.*[9] reported a HR-HPV prevalence of 85.6% in 760 MSM from the Spanish AIDS Research Network (RIS) HPV-Cohort (CoRIS-HPV); 61.6% of these patients were infected by more than two different HR-HPV genotypes.

Anal cancer is infrequent in general population; however, it has become one of the most common emerging non-AIDS-defining cancers in western countries,[10–13] as HIV-infected MSM are at higher risk.[11] Several studies have shown an increase in the incidence of both anal intraepithelial neoplasia (AIN) and in invasive anal cancer in HIV-infected men.[12,14–19]

Even with the advent of highly active antiretroviral therapy (HAART), anal cancer incidence in HIV-infected subjects has not been reduced in the United States,[11,12,20–23] Australia[24] or in European countries, such as France[13] or England.[10]

Key words: HIV, HPV, anal, cytology, squamous intraepithelial lesion
Abbreviations: AIN: anal intraepithelial neoplasia; ASCUS: atypical squamous cells of uncertain significance; cART: combined antiretroviral treatment; CI: confidence intervals; HAART: highly active antiretroviral therapy; HRA: high-resolution anoscopy; HR-HPV: high-risk human papillomavirus; HSIL: high-grade squamous intraepithelial lesion; IQR: interquartile range; LSIL: low-grade squamous intraepithelial lesion; MSM: men who have sex with men; OR: odds ratios; SIL: squamous intraepithelial lesions
Grant sponsor: Spanish Ministry of Science and Innovation [Fondo de Investigación Sanitaria (FIS)]; **Grant numbers:** PI06/0372; PS09/2181; RD06/0006
DOI: 10.1002/ijc.28102
History: Received 16 Aug 2012; Accepted 23 Jan 2013; Online 12 Feb 2013
Correspondence to: Beatriz Hernández-Novoa, Enfermedades Infecciosas, 4ª Planta Ctro, Control A. Laboratorio, Hospital Ramón y Cajal, Ctra. de Colmenar Km 9100, 28034 Madrid, Spain,
Tel.: +34–91-3368711, Fax: +34–91-3368792,
E-mail: bhnovoa@salud.madrid.org

What's new?
Anal squamous intraepithelial lesions (SILs) have been implicated as a risk factor for anal cancer in HIV-positive men who have sex with men (MSM), and now, as detailed in this report, it appears that their development is associated with high risk (HR) human papillomavirus (HPV) genotype burden. Analysis of patients enrolled in the Spanish AIDS Research Network Cohort (CoRIS) revealed a seven-fold increase in SIL risk for HIV-positive MSM who had five or more detectable HR-HPV genotypes. The findings could influence the development of SIL screening programs.

Moreover, most studies show an increase in the incidence of anal cancer when comparing post-HAART to pre-HAART era.[10–12,20,22–25] There is no apparent correlation among the risk of developing invasive anal cancer and the CD4 T-cell count.[16,26]

Anal squamous intraepithelial lesions (SIL), particularly high-grade lesions, are thought to be the precursors of anal cancer, either determined by cytology (anal SIL) or by biopsy (AIN), and several reports have shown that its prevalence is high in HIV-positive MSM.[3,6,7,27–34] In our country, only one group has published data on this field. In 1996, they reported 48.0% of overall prevalence of anal cytology abnormalities in HIV-infected MSM ($n = 52$),[4] and in a recent study of condylomata in their HIV-infected cohort, they also reported high prevalence of anal SIL in MSM.[8]

In Spain, as in most parts of the world, currently no protocols or guidelines exist regarding screening, follow-up and treatment of HPV-associated anal SIL in HIV-infected MSM. Our study aims to determine the prevalence of anal SIL using liquid cytology and the associated risk factors in a large ongoing multicenter cohort of HIV-infected MSM in Spain, CoRIS-HPV.

Methodology

Subjects and methods

CoRIS-HPV is a cohort study within CoRIS, an open, prospective and multicenter cohort of adult patients with confirmed HIV infection and naïve to antiretroviral treatment at study entry, established in January 2004 in 30 sites from 13 of Spain's 17 Autonomous Communities. CoRIS is the cohort of the Spanish Network of Excellence on HIV/AIDS Research (RIS in Spanish) and collects baseline and follow-up sociodemographic (age, sex, category of transmission of HIV, educational level and geographical origin), clinical (AIDS and non-AIDS-defining conditions), immunological (CD4 T-cell counts), virological (HIV viral load), antiretroviral treatment and vital status data (including cause of death). CoRIS is linked to a BioBank. Patients are followed up periodically in accordance with routine clinical practice, usually every 4 months, and data are subjected to internal quality controls. An external audit of 10.0% of subjects is conducted biannually. Ethics approval by the coordinating center (Instituto de Salud Carlos III) and the corresponding hospitals and signed informed consent were obtained.

CoRIS-HPV was set up in 2007 with the objective to study the epidemiology of HR-HPV infection in MSM. Of the 30 sites that contributed data to CoRIS, 12 sites were located in seven different Autonomous Communities and are also part of CoRIS-HPV. Participants were informed about the nature of the study and were required to sign an *ad hoc* informed consent. Specific ethics approval for our study was also obtained. In addition to the variables collected in CoRIS, subjects in CoRIS-HPV were requested to answer a questionnaire on sexual behavior (age of first sexual intercourse, number of lifetime sexual partners, number of sexual partners in the preceding 12 months and frequency of unprotected intercourse in the preceding 12 months), history of genital warts and tobacco use. Subjects were informed that the data contained in this questionnaire will not be passed onto their clinical chart or to their regular physician. Baseline and follow-up anal samples were collected annually (or more often if clinically indicated) and processed for HR-HPV DNA detection; liquid cytologies were performed at the same time points.

HPV DNA detection and genotyping

Samples were collected with a cytobrush and placed in 1 ml of Specimen Transport Medium (Digene Corporation, Gaithersburg, MD) and sent to the Retroviruses and Papillomavirus Unit of the National Centre for Microbiology in Madrid and stored at −20°C until required for testing. DNA was extracted from a 200-μl aliquot of the original anal sample using an automatic DNA extractor (Biorobot M48 Robotic Workstation; Qiagen, Valencia, CA). For quality control, a negative control (PCR quality water) and a positive control (SiHa cells infected with HPV 16) were included in each DNA extraction run (ten-sample batch). Anal HR-HPV infection was determined with "Amplicor HPV DNA Test" (Roche Molecular Systems, Branchburg, NJ), which detects 13 HR-HPV types (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 and 68), and an additional primer set for the human β-globin gene was used to provide a control for cell adequacy, extraction and amplification. The results were considered satisfactory if the β-globin or HPV amplification was detectable and controls' results were valid. All positive samples were genotyped using PCR amplification followed by reverse line blot hybridization using Linear Array® HPV Genotyping test (Roche Molecular Systems).

Liquid cytologies

Anal cytology samples were obtained in a blinded fashion. We used an endocervical brush device for greater yield of cell collection (Cytobrush®, Hologic, Bedford, MA). The cytobrush was inserted into the anal canal until it bypassed the internal sphincter and met the distal rectal wall. It was

rotated in a corkscrew fashion as it was withdrawn in order to sample cells from all areas of the anal canal, bending it slightly with gentle pressure to allow for adequate collection of cells. Once removed, cells were completely resuspended in the Thinprep® vial in PreservCyt® solution (Hologic) and stored according to the manufacturer's recommendations. Cellularity was evaluated together with the presence of glandular cells or cells from the transformation zone, as well as morphologic alterations of the squamous cells. Results were given according to the cervical cytology Bethesda 2001 classification adapted to anal samples. The following categories were established: inadequate sample (not enough cells for diagnosis present), negative for intraepithelial lesion, atypical squamous cells of uncertain significance (ASCUS), low-grade SIL (LSIL) or high-grade SIL (HSIL). As no cases of squamous cell carcinoma were diagnosed, this category was dismissed. All samples were read in a blinded fashion (with no access to the HR-HPV results or the rest of the study variables); most of them (83.0%) were read by two independent cytologists, and those with discordant results were re-evaluated to achieve a consensus diagnosis. In addition, an effort was done in order to avoid the overdiagnosis of ASCUS, that is, as there was scarce cellularity, slides were carefully examined to shift the diagnosis to "negative," "LSIL" or "HSIL" when possible.

Definition of variables

The outcome variable, anal cytology results, was classified as a dichotomous variable in which abnormal results—excluding ASCUS—"LSIL and HSIL" were joined and compared to negative cytologies. As ASCUS can derive to the absence of lesion or to the complete spectrum of cellular alterations, we considered that categorizing them as abnormal results would lead to overdiagnosis of anal SIL. Sensitivity analyses including ASCUS were also performed. The independent variables tested in the analyses were age (categorized by quartiles as $\leq$28, 29–33, 34–39 and $\geq$40 years), number of lifetime sexual partners and also in the last 12 months (categorized by quartiles), age at first sexual intercourse (categorized by median age), educational level (categorized as none/primary, secondary and university), geographical origin (categorized as Spanish, Latin-American and others), CD4 T-cell count closest (within $\pm$6 months) to cytology sampling (treated as continuous variable and categorized, according to most HIV treatment initiation recommendations, as $\leq$350, 351–500 and $\geq$501 cells per millimeter cubed), baseline viral load copies per milliliter (categorized as $>$100,000 and $\leq$100,000), combined antiretroviral treatment (cART) use at CoRIS-HPV cohort entry and number of HR-HPV types.

Statistical analysis

We analyzed subjects up to April 2011. Descriptive analyses of the subjects' characteristics were performed. Frequency distributions are presented for qualitative variables; means and their standard deviation are presented for quantitative variables with symmetrical distributions and the median and interquartile range (IQR) when the distribution is asymmetric. We used the χ^2 test for the comparison of qualitative variables, analysis of variance for the comparison of means and nonparametric tests for the comparison of medians.

The association between abnormal cytological results and the exposure variables was analyzed using multivariate logistic regression models. We also performed separate analyses for LSIL and HSIL. Crude and adjusted odds ratios (ORs) with their 95% confidence intervals (CIs) were obtained as the measure of association. We used likelihood ratio tests and Wald tests to derive *p*-values. A significance level of $<$0.1 was chosen to select the variables entering the multivariate logistic regression model. A backward approach was chosen, and the variables included in the final regression models were those that maximized the likelihood values. Only variables that retained statistically significant associations with the outcome variable were left in multivariate analyses. For all of the above-described models, robust methods were used to estimate the CIs, assuming correlation among subjects recruited within each center and independence among subjects from different centers. The analyses were conducted using Stata 11 (StataCorp LP, College Station, TX).

Results

As of April 2011, CoRIS-HPV comprised 551 MSM with a baseline liquid cytology obtained at the first visit. We analyzed 450 MSM with a valid baseline liquid cytology result, that is, negative for intraepithelial lesion, LSIL or HSIL; excluding inadequate samples and ASCUS (Fig. 1). The excluded 101 patients did not differ in terms of clinical or demographic characteristics.

Most patients (53.2%) were aged younger than 34 years (median age = 33 years, IQR = 28–39 years), 62.0% were Spanish, 80.3% had undergone secondary or university studies and 44.0% were active smokers (Table 1). Seventy-eight percent of the subjects had more than 350 CD4 T cells per millimeter cubed at study entry (Table 1), and overall, 16.0% had started cART at CoRIS-HPV cohort entry. Overall,



Figure 1. Cytological samples included in the analyses.

Table 1. Descriptive analysis of 450 MSM with baseline liquid cytology

	Total
	N (%)
	450 (100)
Age (years)	
≤28	113 (25.0)
29–33	127 (28.2)
34–39	109 (24.2)
≥40	101 (22.4)
Area of origin	
Spain	279 (62.0)
Latin-America	138 (30.7)
Others	28 (6.2)
Unknown	5 (1.0)
Educational level	
None/primary	77 (17.0)
Secondary	175 (39.0)
University	186 (41.3)
Unknown	12 (2.7)
Tobacco use	
Current smoker	197 (43.8)
Past smoker	16 (3.5)
Never smoker	222 (49.3)
Unknown	15 (3.3)
Unsafe sex in last 12 months	
No	101 (22.4)
Yes	344 (76.4)
Unknown	5 (1.2)
Unprotected anal intercourse	
Sometimes	206 (60.7)
Frequently	29 (8.5)
Always	104 (30.7)
Age at first sexual intercourse (years)	
≤17	265 (59.0)
≥18	170 (37.7)
Unknown	15 (3.3)
Number of lifetime sexual partners	
≤40	104 (23.0)
41–100	122 (27.0)
101–400	72 (16.0)
≥401	99 (22.0)
Unknown	53 (12.0)
Number of sexual partners in last 12 months	
≤3	122 (27.0)
4–10	93 (20.7)
11–36	98 (20.7)
≥37	124 (21.0)
Unknown	47 (10.4)
Baseline CD4 T cells per millimeter cubed	
≤350	83 (18.4)
351–500	120 (26.7)
≥501	231 (51.3)
Unknown	16 (3.6)
Baseline viral load copies per milliliter	
>100,000	63 (14)
≤100,000	368 (81.8)
Unknown	19 (4.2)
cART use at CoRIS-HPV cohort entry	
No	373 (82.9)
Yes	72 (16.0)
Unknown	5 (1.1)
Number of HR-HPV genotypes ($n = 368$)	
1	82 (22.3)
2	109 (29.6)
3	85 (23.0)
4	52 (14.1)
≥5	40 (11.0)

Abbreviations: MSM: men who have sex with men; HR-HPV: high-risk human papillomavirus.

38.0% had positive syphilis serology (by treponemic tests) and 26.4% recalled having had condylomas at some time point; however, in 81.4% of the cases, the location was perianal (data not shown).

As to the number of sexual partners, 65.0% had more than 41 partners along their lifetime and 47.7% had between one and ten companions in the last year. Fifty-nine percent of the MSM had their first sexual intercourse before the age of 17 years. Up to three quarters of the patients reported having unprotected sex in the preceding year. Among those who acknowledged having high-risk sexual practices, 61.0% of them admitted to having had protected sex sporadically and in 30.7% of the cases never using condoms.

Overall HR-HPV prevalence was 81.7% (95% CI, 78.0 to 85.2); among patients positive for HR-HPV detection, 22.3% had only one HR-HPV type, 29.6% two types, 23.0% three types, 14.1% four types and 11.0% five or more types. Multiple infections, defined as bearing two or more HR-HPV genotypes, were detected in 77.7% of the cases.

Baseline liquid cytology results in 551 MSM were as follows: 37.0% negative for intraepithelial lesion, 9.0% ASCUS,



Figure 2. Cytological results of 551 MSM at baseline.

41.0% LSIL, 4.0% HSIL and 9.0% were inadequate samples (Fig. 2). All samples bearing HSIL were positive for HR-HPV, and for those with available genotype results, all had more than two types. As for LSIL samples, 89.7% were positive for HR-HPV, and for those with available genotype results, 82.0% had more than two HR-HPV types. Finally, among the negative cytologies, 76.5% had HR-HPV, and for those with available genotype results, 69.1% had more than two types. Overall prevalence of anal SIL (comprising LSIL and HSIL and excluding ASCUS) was 54.7% (95% CI = 50.0–59.3).

The results of the univariate analysis of the 450 valid baseline anal liquid cytologies from patients with available data for all study variables are shown in Table 2. We observed an increase in the risk of anal SIL according to the number of genotypes detected, in a gradual fashion (p-trend < 0.01). Patients with five or more HR-HPV genotypes had a risk of anal SIL seven times greater than those infected by just one HR-HPV genotype (OR = 7.2; 95% CI = 2.7–19.1). Although the overall p-value for the variable age was not significantly associated to the presence of anal SIL, men aged older than 40 years had a statistically significant lower risk of anal SIL (40.0%) than those aged 28 years or younger (OR = 0.6; 95% CI = 0.4–0.9). No statistically significant differences were observed according to geographical origin ($p = 0.42$), educational level ($p = 0.79$) and smoking habit ($p = 0.79$) or with other sexual behavior-related variables such as number of partners in the last 12 months ($p = 0.84$) or having had anal intercourse without condom in the last 12 months ($p = 0.93$; Table 2). With regards to CD4 T-cell count analyzed as a continuous variable, no statistically significant differences were observed when comparing the median CD4 count in MSM with or without anal SIL. When treated as categorical, no associations were observed with the CD4 count-defined cutoff values ($p = 0.32$). Sensitivity tests with different cutoff values were performed, and the results remained unchanged (data not shown).

In the multivariate analyses, only age and number of HR-HPV types entered the models, and only the number of HR-HPV genotypes was significantly associated with the risk of anal SIL. The higher the number of HR-HPV types, the greater the odds of anal SIL; MSM with five or more HR-HPV genotypes had an OR of anal SIL seven times higher (OR = 7.4; 95% CI = 2.8–19.6) than those with one HR-HPV genotype.

Sensitivity analyses were performed including ASCUS in the anal SIL category, and the results were unchanged (data not shown).

We conducted additional analyses to model predictors of HSIL compared to MSM with normal cytologies. Although numbers are small, the only risk factor associated with HSIL was, too, the number of HR-HPV types (data not shown).

Discussion

Half of the HIV-positive MSM in our cohort had baseline anal SIL, the majority were low-grade lesions and the only risk factor associated was the number of HR-HPV types. Similar to that of previously published studies, the prevalence of anal SIL detected in HIV-positive MSM in our cohort was 54.7%.[7,30,35–37] We only detected a 4% of HSIL, in the range of that described by other authors.[30,35,37] In contrast, some studies reported lower levels of LSIL from 23.0 to 26.0%[30,35,37] at the expense of high rates of ASCUS from 15.0[30] to 33.0%.[35,37] In this sense, the ASCUS rate has been defined as a cytology quality control tool, and the rate of ASCUS that we have found is in the range of acceptability.

The only risk factor associated to the presence of anal SIL in our population was infection by multiple HR-HPV types. HIV-positive MSM coinfected with five or more HR-HPV genotypes had seven times higher risk of anal SIL than those with only one genotype. There is little data relative to the risk of detecting anal SIL in HIV-infected MSM according to the presence of multiple HR-HPV coinfections.

Concomitant infection by more than one HR-HPV genotype has been associated to the presence[6,38,39] or progression of AIN.[35] Early reports by Palefsky *et al.* showed the association between the presence of more than one HPV genotype and the progression[40] or incidence[41] of anal SIL. A report by Conley *et al.*[30] has shown association between the higher number of HR-HPV genotypes and the presence of anal SIL; however, the analysis was globally done and comprised MSM, heterosexual men and women. To our knowledge, the only previous study assessing the relationship between the presence of anal SIL and multiple HPV infections in HIV-infected MSM reported that the risk of having anal SIL doubled when ≥3 HPV genotypes were present compared to single infection, although both low-risk and HR-HPV types were analyzed together.[31]

In the univariate analysis, we found that MSM aged 33 years or younger were more likely to have anal SIL; however, this association was not found after the multivariate analysis

Table 2. Univariate analysis of anal SIL in MSM

	Total *N* (%) 246/450 (54.7)	OR (95% CI)	*p*-value
Age (years)			
≤28	64/113 (56.6)	1	
29–33	79/127 (62.2)	1.3 (0.8–2.1)	0.08
34–39	57/109 (52.3)	0.8 (0.5–1.4)	0.04[1]
≥40	46/101 (45.5)	0.6 (0.4–0.9)	
Area of origin			
Spain	156/279 (56.0)	1	
Latin-America	75/138 (54.4)	0.9 (0.6–1.4)	0.42
Others	12/28 (43.0)	0.6 (0.3–1.3)	
Educational level			
None/primary	44/77 (57.2)	1	
Secondary	92/175 (52.6)	0.8 (0.5–1.4)	0.79
University	102/186 (55.0)	0.9 (0.5–1.6)	
Tobacco use			
Current smoker	107/197 (54.3)	1	
Past smoker	10/16 (62.5)	1.4 (0.5–4.0)	0.79
Never smoker	119/222 (53.6)	1.0 (0.7–1.4)	
Risk sexual behaviors in last 12 months			
No	55/101 (54.5)	1	
Yes	189/344 (55.0)	1.0 (0.7–1.6)	0.93
Unprotected sexual intercourse			
Sometimes	111/207 (53.6)	1	
Frequently	13/29 (44.8)	0.7 (0.3–1.6)	0.26
Always	63/104 (60.6)	1.3 (0.8-2.2)	
Age at first sexual intercourse (years)			
≤17	148/265 (56.0)	1	
≥18	91/170 (53.5)	0.9 (0.6–1.3)	0.64
Number of lifetime sexual partners			
≤40	57/104 (55.0)	1	
41–100	64/122 (52.5)	0.9 (0.5–1.5)	0.46
101–400	39/72 (54.2)	1.0 (0.5–1.8)	
≥401	62/99 (62.6)	1.4 (0.8–2.4)	
Number of sexual partners in last 12 months			
≤3	69/122 (56.6)	1	
4–10	50/93 (53.8)	0.9 (0.5–1.5)	0.84
11–36	56/93 (60.2)	1.2 (0.7–2.0)	
≥37	53/95 (55.8)	1.0 (0.6–1.6)	
Baseline CD4 T cells per millimeter cubed			
≤350	52/83 (62.7)	1	
351–500	63/120 (52.5)	0.7 (0.4–1.2)	0.32
≥501	126/231 (54.6)	0.7 (0.4–1.2)	
Number of HR-HPV genotypes			
1	36/82 (44.0)	1	

Table 2. Univariate analysis of anal SIL in MSM (Continued)

	Total		
	N (%)		
	246/450 (54.7)	OR (95% CI)	*p*-value
2	61/109 (56.0)	1.6 (0.9–2.9)	<0.01
3	50/85 (59.0)	1.8 (1.0–3.4)	<0.01[1]
4	38/52 (73.0)	3.5 (1.6–7.4)	
≥5	34/40 (85.0)	7.2 (2.7–19.1)	

[1]*p*-trend. Abbreviations: MSM: men who have sex with men; SIL: squamous intraepithelial lesion; OR: odds ratio; HR-HPV: high-risk human papillomavirus.
Bold values are statistically significant.

as it was confounded by the higher prevalence of multiple HPV coinfections in the younger group.

We explored the relationship between CD4 T-cell counts and the presence of anal SIL; however, we did not find any association. This fact has also been documented in previous studies in which no association between CD4 T-cell counts and anal SIL was found in HIV-positive MSM[7,32,34,42]; however, the study of Wilkin *et al.*[34] included heterosexual men in the analysis. On the contrary, other studies have reported that a low CD4 T-cell count has been associated with the development of anal SIL.[28,34] In relation to this, the fact that in our cohort more than 78.0% of the subjects had more than 350 CD4 T cells per millimeter cubed could account for the lack of association with anal SIL.

Some studies have also investigated the association between AIN or anal SIL and nadir CD4 T-cell count, and all have shown that HIV-positive MSM with a low nadir CD4 T-cell count had higher risk of anal SIL or AIN.[30,34,43] Given our study was nested in a young cohort of naïve patients in which only 16.0% of MSM had already started cART, we have not been able to explore the role of nadir CD4 T-cell count as yet; however, further follow-up of the cohort will allow for this exploration.

Although it could be expected that variables reflecting sexual behavior would be related to the presence of anal SIL, we did not observe any association with the number of sexual partners, unprotected sex or the age of first sexual intercourse. Previous analysis of the same cohort has shown that the only risk factor associated with HR-HPV infection was the number of lifetime sexual partners,[44] as reported by other studies.[45–47]

Cigarette smoking plays a role in the etiology of anogenital cancers[48,49]; however, other studies found no association with the presence of HR-HPV infection or the incidence of HSIL.[33] Likewise, in our study, we did not observe an association with smoking habits and the presence of anal SIL.

Although we do not have high-resolution anoscopy (HRA)-guided biopsy confirmation for the great majority of the anal SIL as yet, these are underway prioritizing HSIL, LSIL and ASCUS. To date, all patients in this study are followed up annually, and only HR-HPV detection and liquid cytology are performed. We are aware that liquid cytology is far from perfect; however, it may be used as a screening tool in high-risk populations like HIV-infected MSM, as recently assessed.[50] No anal screening program has been established in Spain as yet, and only few centers have the resources to implement HRA.

In summary, these are the baseline data from a large ongoing multicenter cohort of young HIV-positive mainly Spanish and highly educated (80.3% had undergone secondary or university studies) MSM followed up in Spain. Our data show that the prevalence of anal SIL is high and that its main risk factor is multiple infections with HR-HPV types; a condition that is indeed very frequent in HIV-positive MSM, the most vulnerable population at risk of anal cancer. The natural history of anal SIL is yet to be determined, and thus, studies such as this one are necessary to uncover the baseline burden of HR-HPV-associated lesions and to advance in the generation of evidence to assess the need of establishing anal SIL screening programs.

Acknowledgements

The authors thank Itziar Sanz for her continuous support, lifelong expertise and wise advice in the implementation of anal cytology reading at the Hospital Universitario Ramon y Cajal-IRYCIS.

CoRIS-HPV group participating centers and members.

Hospital Universitario San Cecilio de Granada: Alejandro Peña and Federico García; **Centro Nacional de Microbiología (ISCIII). Madrid**: Marta Ortiz and Montserrat Torres; **Hospital Xeral de Vigo:** Antonio Ocampo, Alfredo Rodriguez Da Silva, Celia Miralles, Gustavo Mauricio Iribarren and Joaquín González-Carreró; **Hospital Universitario Ramón y Cajal-IRYCIS. Madrid:** Beatriz Hernández-Novoa, Nadia Madrid, Amparo Benito and Itziar Sanz; **Centro Sanitario Sandoval. Madrid:** Jorge del Romero, Mar Vera, Carmen Rodríguez, Carmen Martín Alegre, Juan Carlos Carrió and Montse Raposo; **Hospital Universitario Virgen del Rocío. Sevilla:** Pompeyo Viciana, Mónica Trastoy and Maria Fontillón; **Hospital Universitario de Elche. Alicante:** Mar Masiá, Cati Robledano, Félix Gutierrez, Sergio Padilla and Encarna Andrada; **Hospital Universitario Severo Ochoa. Madrid:** Miguel Cervero; **Hospital San Pedro-CIBIR. La Rioja:** José Ramón Blanco and Laura Pérez; **Hospital General Universitario de Alicante. Alicante:** Joaquín Portilla and Irene Portilla; **Hospital Universitario Donostia. San Sebastián:** Miguel Ángel Vonwichmann, Jose Antonio Iribarren and Xabier Camino; **Hospital Universitario La Paz-Idi-PAZ. Madrid:** Elena Sendagorta and Pedro Herranz; **Hospital Universitario de Canarias. Santa Cruz de Tenerife:** Patricia Rodríguez, Juan Luis Gómez and Dacil Rosado; **Centro Nacional de Epidemiología (ISCIII). Madrid:** Julia del Amo, Cristina González and Mª Angeles Rodríguez. **Institut Català d'Oncologia. L'Hospitalet de Llobregat.** Silvia de Sanjosé.

References

1. Frisch M, Glimelius B, van den Brule AJ, et al. Sexually transmitted infection as a cause of anal cancer. *N Engl J Med* 1997;337:1350–8.
2. Lacey HB, Wilson GE, Tilston P, et al. A study of anal intraepithelial neoplasia in HIV positive homosexual men. *Sex Transm Infect* 1999;75: 172–7.
3. Palefsky JM, Holly EA, Ralston ML, et al. Prevalence and risk factors for human papillomavirus infection of the anal canal in human immunodeficiency virus (HIV)-positive and HIV-negative homosexual men. *J Infect Dis* 1998;177:361–7.
4. Sirera G, Videla S, Pinol M, et al. High prevalence of human papillomavirus infection in the anus, penis and mouth in HIV-positive men. *AIDS* 2006;20:1201–4.
5. de Pokomandy A, Rouleau D, Ghattas G, et al. Prevalence, clearance, and incidence of anal human papillomavirus infection in HIV-infected men: the HIPVIRG cohort study. *J Infect Dis* 2009;199:965–73.
6. Palefsky JM, Holly EA, Efirdc JT, et al. Anal intraepithelial neoplasia in the highly active antiretroviral therapy era among HIV-positive men who have sex with men. *AIDS* 2005;19:1407–14.
7. Piketty C, Darragh TM, Heard I, et al. High prevalence of anal squamous intraepithelial lesions in HIV-positive men despite the use of highly active antiretroviral therapy. *Sex Transm Dis* 2004;31:96–9.
8. Darwich L, Cañadas M, Videla S, et al. Condylomata, cytological abnormalities and human papillomavirus infection in the anal canal in HIV-infected men. *HIV Med* 2012;13:549–57.
9. Ortiz M, Torres M, González C, et al. High-risk HPV (HR-HPV) prevalence by HIV-1 status in Spanish men who have sex with men (MSM) in an out patient sexually transmitted diseases clinic and in a prospective cohort of HIV-positive MSM belonging to Spanish Multicenter Cohort (CoRIS), Presented at the 17th Conference on Retroviruses and Opportunistic Infections (CROI), San Francisco, CA, February 16–19, 2010.
10. Bower M, Powles T, Newsom-Davis T, et al. HIV-associated anal cancer: has highly active antiretroviral therapy reduced the incidence or improved the outcome? *J Acquir Immune Defic Syndr* 2004;37:1563–5.
11. D'Souza G, Wiley DJ, Li X, et al. Incidence and epidemiology of anal cancer in the multicenter AIDS cohort study. *J Acquir Immune Defic Syndr* 2008;48:491–9.
12. Patel P, Hanson DL, Sullivan PS, et al. Incidence of types of cancer among HIV-infected persons compared with the general population in the United States, 1992–2003. *Ann Intern Med* 2008;148:728–36.
13. Piketty C, Selinger-Leneman H, Grabar S, et al. Marked increase in the incidence of invasive anal cancer among HIV-infected patients despite treatment with combination antiretroviral therapy. *AIDS* 2008;22:1203–11.
14. Chiao EY, Krown SE, Stier EA, et al. A population-based analysis of temporal trends in the incidence of squamous anal canal cancer in relation to the HIV epidemic. *J Acquir Immune Defic Syndr* 2005;40:451–5.
15. Diamond C, Taylor TH, Aboumrad T, et al. Increased incidence of squamous cell anal cancer among men with AIDS in the era of highly active antiretroviral therapy. *Sex Transm Dis* 2005;32:314–20.
16. Frisch M, Biggar RJ, Goedert JJ. Human papillomavirus-associated cancers in patients with human immunodeficiency virus infection and acquired immunodeficiency syndrome. *J Natl Cancer Inst* 2000;92:1500–10.
17. Lanoy E, Spano JP, Bonnet F, et al. The spectrum of malignancies in HIV-infected patients in 2006 in France: the ONCOVIH study. *Int J Cancer* 2011;129:467–75.
18. Melbye M, Cote TR, Kessler L, et al. High incidence of anal cancer among AIDS patients. The AIDS/Cancer Working Group. *Lancet* 1994;343:636–9.
19. Panther LA, Schlecht HP, Dezube BJ. Spectrum of human papillomavirus-related dysplasia and carcinoma of the anus in HIV-infected patients. *AIDS Read* 2005;15:79–82, 85–6, 88, 91.
20. Crum-Cianflone NF, Hullsiek KH, Marconi VC, et al. Anal cancers among HIV-infected persons: HAART is not slowing rising incidence. *AIDS* 2010;24:535–43.
21. Engels EA, Biggar RJ, Hall HI, et al. Cancer risk in people infected with human immunodeficiency virus in the United States. *Int J Cancer* 2008;123:187–94.
22. Hessol NA, Pipkin S, Schwarcz S, et al. The impact of highly active antiretroviral therapy on non-AIDS-defining cancers among adults with AIDS. *Am J Epidemiol* 2007;165:1143–53.
23. Seaberg EC, Wiley D, Martinez-Maza O, et al. Cancer incidence in the multicenter aids cohort study before and during the HAART era: 1984 to 2007. *Cancer* 2010;116:5507–16.
24. van Leeuwen MT, Vajdic CM, Middleton MG, et al. Continuing declines in some but not all HIV-associated cancers in Australia after widespread use of antiretroviral therapy. *AIDS* 2009;23:2183–90.
25. Simard EP, Pfeiffer RM, Engels EA. Cumulative incidence of cancer among individuals with acquired immunodeficiency syndrome in the United States. *Cancer* 2011;117:1089–96.
26. Frisch M, Biggar RJ, Engels EA, et al. Association of cancer with AIDS-related immunosuppression in adults. *JAMA* 2001;285:1736–45.
27. Palefsky JM. Anal human papillomavirus infection and anal cancer in HIV-positive individuals: an emerging problem. *AIDS* 1994;8:283–95.
28. Palefsky JM, Holly EA, Ralston ML, et al. Anal squamous intraepithelial lesions in HIV-positive and HIV-negative homosexual and bisexual men: prevalence and risk factors. *J Acquir Immune Defic Syndr Hum Retrovirol* 1998;17:320–6.
29. Chin-Hong PV, Berry JM, Cheng SC, et al. Comparison of patient- and clinician-collected anal cytology samples to screen for human papillomavirus-associated anal intraepithelial neoplasia in men who have sex with men. *Ann Intern Med* 2008;149:300–6.
30. Conley L, Bush T, Darragh TM, et al. Factors associated with prevalent abnormal anal cytology in a large cohort of HIV-infected adults in the United States. *J Infect Dis* 2010;202: 1567–76.
31. Friedman HB, Saah AJ, Sherman ME, et al. Human papillomavirus, anal squamous intraepithelial lesions, and human immunodeficiency virus in a cohort of gay men. *J Infect Dis* 1998;178:45–52.
32. Li AH, Phanuphak N, Sahasrabuddhe VV, et al. Anal squamous intraepithelial lesions among HIV positive and HIV negative men who have sex with men in Thailand. *Sex Transm Infect* 2009;85:503–7.
33. Palefsky JM, Holly EA, Ralston ML, et al. Anal cytological abnormalities and anal HPV infection in men with Centers for Disease Control group IV HIV disease. *Genitourin Med* 1997;73:174–80.
34. Wilkin TJ, Palmer S, Brudney KF, et al. Anal intraepithelial neoplasia in heterosexual and homosexual HIV-positive men with access to antiretroviral therapy. *J Infect Dis* 2004;190:1685–91.
35. de Pokomandy A, Rouleau D, Ghattas G, et al. HAART and progression to high-grade anal intraepithelial neoplasia in men who have sex with men and are infected with HIV. *Clin Infect Dis* 2011;52:1174–81.
36. Salit IE, Lytwyn A, Raboud J, et al. The role of cytology (Pap tests) and human papillomavirus testing in anal cancer screening. *AIDS* 2010;24:1307–13.
37. Weis SE, Vecino I, Pogoda JM, et al. Prevalence of anal intraepithelial neoplasia defined by anal cytology screening and high-resolution anoscopy in a primary care population of HIV-infected men and women. *Dis Colon Rectum* 2011;54: 433–41.
38. De Vuyst H, Clifford GM, Nascimento MC, et al. Prevalence and type distribution of human papillomavirus in carcinoma and intraepithelial neoplasia of the vulva, vagina and anus: a meta-analysis. *Int J Cancer* 2009;124:1626–36.
39. Salit IE, Tinmouth J, Chong S, et al. Screening for HIV-associated anal cancer: correlation of HPV genotypes, p16, and E6 transcripts with anal pathology. *Cancer Epidemiol Biomarkers Prev* 2009;18:1986–92.
40. Palefsky JM, Holly EA, Hogeboom CJ, et al. Virologic, immunologic, and clinical parameters in the incidence and progression of anal squamous intraepithelial lesions in HIV-positive and HIV-negative homosexual men. *J Acquir Immune Defic Syndr Hum Retrovirol* 1998;17:314–19.
41. Palefsky JM, Holly EA, Ralston ML, et al. High incidence of anal high-grade squamous intra-epithelial lesions among HIV-positive and HIV-negative homosexual and bisexual men. *AIDS* 1998;12:495–503.
42. Payam A, Shiramizu B, Shikuma C, et al. HIV-associated anal dysplasia: experience from a multiethnic-HIV clinic in Hawaii. *J Health Care Poor Underserved* 2011;22:16–22.
43. Scott H, Khoury J, Moore BA, et al. Routine anal cytology screening for anal squamous intraepithelial lesions in an urban HIV clinic. *Sex Transm Dis* 2008;35:197–202.
44. Del Amo J, González C, Geskus RB, et al.; on behalf of CoRIS-HPV Study Group. What drives the number of high risk human papillomavirus types in the anal canal in HIV-positive men who have sex with men? *J Infect Dis*, in press.
45. Chin-Hong PV, Vittinghoff E, Cranston RD, et al. Age-specific prevalence of anal human papillomavirus infection in HIV-negative

sexually active men who have sex with men: the EXPLORE study. *J Infect Dis* 2004;190: 2070–6.
46. Nyitray AG, Carvalho da Silva RJ, Baggio ML, et al. Age-specific prevalence of and risk factors for anal human papillomavirus (HPV) among men who have sex with women and men who have sex with men: the HPV in men (HIM) study. *J Infect Dis* 2011;203:49–57.
47. Vajdic CM, van Leeuwen MT, Jin F, et al. Anal human papillomavirus genotype diversity and co-infection in a community-based sample of homosexual men. *Sex Transm Infect* 2009;85: 330–5.
48. Palefsky JM, Shiboski S, Moss A. Risk factors for anal human papillomavirus infection and anal cytologic abnormalities in HIV-positive and HIV-negative homosexual men. *J Acquir Immune Defic Syndr* 1994;7: 599–606.
49. Daling JR, Sherman KJ. Relationship between human papillomavirus infection and tumours of anogenital sites other than the cervix. *IARC Sci Publ* 1992:223–41.
50. Darragh TM, Tokugawa D, Castle PE, et al. Interrater agreement of anal cytology. *Cancer Cytopathol* 2013;121:72–8.